Read-Gene S.A. engages in the detection, prevention, and treating of various types of cancer in Poland. The company offers chemoprevention that uses natural or synthetic substances to inhibit, reverse, or delay the process of developing cancer. It also provides clinical trials that involves evaluating whether a potential drug, product, or medical technology is effective and safe for the medical, pharmaceutical, chemical, and biotechnological industries. In addition, the company offers genetic tests; and advisory services for genetic counseling and support for oncological genetic counseling centers. Further, it operates an online platform for genetic tests and genetic-oncological consultations. The company was incorporated in 2005 and is based in Szczecin, Poland. Read-Gene S.A. operates as a subsidiary of Gen-Pat-Med Sp. z o.o.
Research context
RDG appears in PyInvesting’s Warsaw Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- PLN
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
No comments yet
Start a focused discussion about RDG.WAR.